Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Leerink Swann cut their Q1 2018 earnings per share estimates for shares of Amicus Therapeutics in a research note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst J. Schwartz now expects that the biopharmaceutical company will post earnings of ($0.37) per share for the quarter, down from their previous forecast of ($0.32). Leerink Swann currently has a “Outperform” rating and a $24.00 price objective on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.36) EPS, FY2018 earnings at ($1.47) EPS, FY2019 earnings at ($1.06) EPS and FY2020 earnings at ($0.85) EPS.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). The business had revenue of $14.73 million for the quarter, compared to the consensus estimate of $14.50 million. Amicus Therapeutics had a negative net margin of 769.03% and a negative return on equity of 71.06%.
A number of other research analysts have also commented on the company. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th. Cowen reiterated a “buy” rating and set a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Robert W. Baird set a $20.00 target price on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $19.06.
Amicus Therapeutics (FOLD) traded up $0.05 on Monday, reaching $15.21. The company’s stock had a trading volume of 1,028,538 shares, compared to its average volume of 3,471,886. The company has a market cap of $2,810.85, a price-to-earnings ratio of -8.31 and a beta of 1.60. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.60 and a quick ratio of 5.53. Amicus Therapeutics has a fifty-two week low of $6.41 and a fifty-two week high of $17.40.
Several institutional investors have recently bought and sold shares of FOLD. Strs Ohio purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $102,000. Birchview Capital LP purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $151,000. Sage Capital Advisors llc purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $154,000. Engineers Gate Manager LP purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $155,000. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $196,000.
In related news, major shareholder Perceptive Advisors Llc purchased 335,827 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The shares were bought at an average price of $13.56 per share, for a total transaction of $4,553,814.12. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jay Barth sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total value of $336,000.00. Following the completion of the sale, the insider now owns 105,409 shares in the company, valued at approximately $1,770,871.20. The disclosure for this sale can be found here. Insiders have sold a total of 207,870 shares of company stock worth $3,066,112 in the last quarter. Company insiders own 3.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2018/03/14/leerink-swann-comments-on-amicus-therapeutics-inc-s-q1-2018-earnings-fold.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.